Preliminary immunohistochemical characterization of a monoclonal antibody (PRO:4-216) prepared from human prostate cancer nuclear matrix proteins

Urology

Volumn 50, Issue 5, 1997, Pages 800-808

  Partin, Alan W ^a   Briggman, Joseph V ^b   Subong, Eric N P ^b   Szaro, Robert ^b   Oreper, Ana ^b   Wiesbrock, Sarah ^b   Meyer, Jane ^b   Coffey, Donald S ^b   Epstein, Jonathan I ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PRO 4 216; NUCLEAR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL NUCLEUS MATRIX; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; ISOELECTRIC POINT; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN ISOLATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NUCLEAR; AUTOANTIBODIES; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED BALB C; NUCLEAR PROTEINS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 0030665370     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00337-3     Document Type: Article

References (32)

1. Boring CC, Squires TS, Tong T, and Montgomery S: Cancer statistics, 1994. CA Cancer J Clin 44: 7-26, 1994.
2. Carter HB, and Coffey DS: Prostate cancer: the magnitude of the problem in the United States, in Coffey DS, Resnick MI, Dorr FA, and Karr JP (Eds): A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer. New York, Plenum, 1988, pp 1-7.
3. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, DeKernionJB, Ratliff TL, Kavoussi LR, Dalkin BL, et al: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151: 1283-1290, 1994.
4. Partin AP, and Oesterling JE: The clinical usefulness of prostate specific antigen: update 1994. J Urol 152: 1358-1368, 1994.
5. Partin AW, Pound CR, Clemens JQ, Epstein JI, and Walsh PC: Serum PSA after anatomic radical prostatectomy: the Johns Hopkins experience after ten years. Urol Clin North Am 20: 713-725, 1993.
6. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, and Andriole GL: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324: 1156-1161, 1991.
7. Pienta KJ, Partin AW, and Coffey DS: Cancer as a disease of DNA organization and dynamic cell structure. Cancer Res 49: 2525-2532, 1989.
8. Partin AW, Getzenberg RH, CarMichael MJ, Vindivich D, Yoo J, Epstein JI, and Coffey DS: Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res 53: 744-746, 1993.
9. Khanuja PS, Lehr JE, Soule HD, Gehani SK, Noto AC, Choudhury S, Chen R, and Pienta KJ: Nuclear matrix proteins in normal and breast cancer cells. Cancer Res 53: 3394-3398, 1993.
10. Keesee SK, Meneghini MD, Szaro RP, and Wu YJ: Nuclear matrix proteins in human colon cancer. Proc Natl Acad Sci USA 91: 1913-1916, 1994.
11. Bidwell JP, Fey EG, vanWijnen AJ, Penman S, Stein JL, Lian JB, and Stein GS: Nuclear matrix proteins distinguish normal diploid osteoblasts from osteosarcoma cells. Cancer Res 54: 28-32, 1994.
12. Fey EG, and Penman S: Nuclear matrix proteins reflect cell type of origin in cultured human cells. Proc Natl Acad Sci USA 85: 121-125, 1988.
13. Wray W, Boulikas T, Wray V, and Hancock R: Silver staining of proteins in polyacrylamide gels. Anal Biochem 118: 197-203, 1981.
14. Galfre G, Howe SC, Milstein C, Butler GW, and Howard JG: Antibodies to major histocompatibility antigens produced by hybrid cell lines. Nature 266: 550-552, 1977.
15. Epstein JI, CarMichael M, and Partin AW: OA-509 (fatty acid synthase) as an independent predictor of pathologic stage in adenocarcinoma of the prostate. Urology 45: 86-90, 1994.
16. Sauvageot J, and Epstein JI: Immunoreactivity for PSA and PSAP in adenocarcinoma of the prostate: relation to progression following radical prostatectomy. Prostate (in press).
17. Frost JK: The Cell in Health and Disease. New York, Karger, 1986, p 1.
18. Lebert H: Traite Pratique des Maladies: Concreuses et des Affections Curables Confondeus avec le Cancer. Paris, JB Basilliere, 1851, p 1.
19. Virchow R: Krankhaften Geschwulste. Berlin, A Hirschward, 1863, p 1.
20. Epstein JI, Berry SJ, and Eggleston JC: Nuclear roundness factor. A predictor of progression in untreated Stage A2 prostate cancer. Cancer 54: 1666-1671, 1984.
21. Partin AW, Walsh AC, Pitcock RV, Mohler JL, Epstein JI, and Coffey DS: A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in Stage A2 prostate cancer: a critical analysis. J Urol 142: 1254-1258, 1989.
22. Partin AW, Steinberg GD, Pitcock RV, Wu L, Piantadosi S, Coffey DS, and Epstein JI: Use of nuclear morphometry, Gleason histologic scoring, clinical stage and age to predict disease free survival among patients with prostate cancer. Cancer 70: 161-168, 1992.
23. Getzenberg RH, Konety BR, Oeler TA, Quigley MM, Hakam A, Becich MJ, and Bahnson BR: Bladder cancer associated nuclear matrix proteins. Cancer Res 56: 1690-1694, 1996.
24. Donat TL, Sakr W, Lehr JE, and Pienta KJ: Unique nuclear matrix protein alterations in head and neck squamous cell carcinomas: intermediate biomarker candidates. Otolaryngol Head Neck Surg 114: 387-393, 1996.
25. Keesee SK, Briggman JV, Thill G, and Wu YJ: Utilization of nuclear matrix proteins for cancer diagnosis. Crit Rev Eukaryotic Gene Expression: 6, 189-214, 1996.
26. Soloway MS, Briggman JV, Carpinito GA, Chodak GW, Church PA, Lamm DL, Lange P, Messing E, Pasciak RM, Reservitz GB, et al: Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 156: 363-367, 1996.
27. Michalik J, Yeoman LC, and Busch H: Nucleolar localization of protein B23 (37/5.1) by immunocytochemical techniques. Life Sci 28: 1371-1379, 1981.
28. Ruschoff J, Bocker T, Buettner R, Bittinger A, Wieland W, and Hofstaedter F: In vivo and ex vivo expression of nucleolar proliferation-associated antigens (p120, B23) in the prostate. Verh Dtsch Ges Pathol 77: 103-106, 1993.
29. Bocker T, Bittinger A, Wieland W, Buettner R, Fauser G, and Hofstaedter F: In vitro and ex vivo expression of nucleolar proteins B23 and p120 in benign and malignant epithelial lesions of the prostate. Mod Pathol 8: 226-231, 1995.
30. Nozawa Y, Van Beizen N, Van der Made AC, Dinjens WN, and Bosman FT: Expression of nucleophosmin/B23 in normal and neoplastic colorectal mucosa. J Pathol 178: 48-52, 1996.
31. Imai H, Ochs RL, Kiyosawa K, Furuda S, Nakamura RM, and Tan EM: Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Pathol 140: 859-870, 1992.
32. Wojno KJ, and Epstein JI: The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases. Am J Surg Pathol 19: 251-260, 1995.